The tests that gate release, and the numbers we publish.
Nothing ships until it passes the assays below, run in our own QC lab at the Cambridge, Massachusetts facility where the lot was made, against acceptance criteria fixed before the lot is produced. The tables on this page use real, representative limits pulled from the catalog, not marketing language like “pharma-grade purity” standing in for a number.
Every protein lot is sequence-confirmed against its reference construct and released against two independent purity measurements, SDS-PAGE and RP-HPLC, because a single band on a gel can hide a co-eluting impurity that a reversed-phase separation catches, and vice versa. Release limits run ≥95–98% depending on the SKU; the exact figure is printed on that product’s datasheet. Because purification and QC sit in the same Cambridge building, a sample goes from the polish column to the gel without a courier in between.
| Test | Method | Representative release limit |
|---|---|---|
| Identity | Sequence-confirmed construct; UniProt / GenBank accession on the datasheet | Matches reference sequence |
| Purity | SDS-PAGE, reducing, Coomassie or silver stain | ≥ 95%, single-band criterion |
| Purity | RP-HPLC, single main peak | ≥ 95–98% depending on SKU |
| Molecular weight | SDS-PAGE against a calibrated ladder | Within the range on the datasheet (e.g. 17.2 kDa for recombinant human FGF2) |
Bacterial endotoxin is tested by the Limulus Amebocyte Lysate (LAL) method on the filled liquid and reported per milliliter (EU/mL); for purified proteins we publish the figure per microgram of protein (EU/µg) alongside it, since that is the unit a dose is set in. Endotoxin above a few tenths of an EU/µg is enough to activate TLR4 signaling in immune and stem cells and confound anything downstream that depends on a quiescent baseline, a common, and often uninvestigated, source of irreproducible cell-culture data. Representative release limits: recombinant proteins around <0.1 EU/µg; formulated media around 1 EU/mL.
Purity confirms a protein folded and stayed intact; it doesn’t confirm it still does the job. Growth factors and cytokines are released against a cell-based bioassay, a responsive cell line is dosed across a concentration series and the response (usually proliferation) is fit to a curve to derive an ED50, the concentration giving half-maximal effect. ED50 is lot-tested against a working reference standard so drift shows up before it reaches you, not after.
| Test | Method | Representative release limit |
|---|---|---|
| FGF2 (bFGF) | Proliferation of BALB/c 3T3 fibroblasts | ED50 0.1–0.6 ng/mL |
| EGF | Proliferation of BALB/c 3T3 fibroblasts | ED50 0.1–0.5 ng/mL |
| IGF-1 | Proliferation of MCF-7 cells | ED50 3–15 ng/mL |
Media and liquid supplements are sterilized by 0.1–0.2 µm membrane filtration and tested to a USP <71>-style method before release, filled units are held, not shipped, until the sterility test comes back clean. Products intended for live cell culture are additionally tested for mycoplasma, which a standard sterility test doesn’t catch. Osmolality and pH are released against the target window on the datasheet, typically pH 7.0–7.4 and 280–340 mOsm/kg by freezing-point depression, depending on the formulation.
Chromatography media are qualified on capacity, not just chemistry. Dynamic binding capacity (DBC) is measured to 10% breakthrough with a reference protein under defined flow and residence-time conditions, ligand leakage is bounded by ELISA against the coupled ligand, and the clean-in-place tolerance printed on the datasheet is validated against the same functionalized lot.
| Test | Method | Representative release limit |
|---|---|---|
| Dynamic binding capacity | Reference protein loaded to 10% breakthrough (e.g. human IgG for Protein A media, 4 min residence) | e.g. 40 mg IgG/mL resin |
| Ligand leakage | ELISA against the ligand, measured in the eluate | e.g. 15 ng leached ligand per mg target protein |
| Clean-in-place tolerance | Exposure to the validated CIP reagent (e.g. 0.1 M NaOH) | ≤ 15 min contact, ≤ 10 cycles before re-qualification |
A unit of enzyme activity only means something with the definition attached, one supplier’s “unit” isn’t necessarily another’s. Every enzyme datasheet spells out its unit definition and the assay used to measure it lot-to-lot, so a titration you ran against a prior lot still means what you think it means.
| Test | Method | Representative release limit |
|---|---|---|
| Taq / hot-start Taq DNA polymerase | Primer-extension incorporation assay | 1 U incorporates 10 nmol dNTP into acid-insoluble material in 30 min at 74 °C |
| Phi29 DNA polymerase | Primer-extension incorporation assay | 1 U incorporates 0.5 nmol dNTP into acid-insoluble material in 10 min at 30 °C |
| Chemically competent cells | Heat-shock transformation with intact pUC19 | Transformation efficiency reported in CFU / µg DNA |
| T4 DNA ligase | Cohesive-end ligation of lambda/HindIII fragments, gel-based | 1 cohesive-end unit gives 50% ligation of HindIII-cut lambda DNA in 30 min at 16 °C in a 20 µL reaction. Not Weiss units. |
What’s actually on the CoA.
Catalog number, product name, and the specific lot number the certificate covers.
Each release assay run against that lot, the acceptance criterion and the measured value, side by side, not just a pass/fail stamp.
The date the lot was released, and the expiry or retest date it's good through.
The condition the result is only valid under, e.g. -80 °C frozen, or 2–8 °C protected from light.
The QA release statement for that lot, the sign-off that the batch record was reviewed and the material met spec.
A CoA is tied to the exact lot number on your vial or bottle, generated by the same Cambridge QC lab that ran the assays, never a catalog-wide typical value. Request a lot-specific CoA →
How a lot gets made
The expression, purification, and fill steps that lead into this QC.
Catalog →Every published spec
The purity, endotoxin, and activity figures, product by product.